Specialty drugmaker Depomed Inc. said Wednesday the USFDA approved a new formulation of the company's diabetes drug Glumetza.
GLUMETZA™ (metformin hydrochloride extended release tablets) is indicated alone or in combination with sulfonylurea or insulin as an adjunct to diet and exercise to improve glycemic control in patients 18 years of age and older with type 2 diabetes.
The FDA approved a 1g tablet, adding to the 500-milligram dose already on the market. The maximum effective dose is about 2,000-milligrams per day, the company said, making the newly approved dose an option for patients looking to take fewer tablets each day.
The drug is used to treat type 2 diabetes, the most common form of the disease.
No comments:
Post a Comment